National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting, 49388 [2020-17677]
Download as PDF
<![CDATA[
49388
Federal Register / Vol. 85, No. 157 / Thursday, August 13, 2020 / Notices
In particular, the claims cover include
transgenic NKs expressing CCR7 and
CD16a (HA–CD16). The treatment
methods also include dependent claims
where the transgenic NK cells are coadministered with a monoclonal
antibody therapeutic (e.g., rituximab).
CCR7 is a chemokine receptor
(chemokine (C—C motif) receptor 7)
known to direct cellular migration to
secondary lymphoid tissues, including
lymph nodes where hematological
malignancies such as diffuse large B cell
lymphoma (DLBCL) reside. Normally,
CCR7 is expressed by only a small
subset of resting primary NK cells.
CD16 includes Fc receptors FcgRIIIa
(CD16a) and FcgRIIIb (CD16b) found on
the surface of natural killer (NK) cells
and other leukocytes. CD16a binds to
the Fc tail of IgG antibodies which then
activates the NK cell for antibodydependent cellular toxicity (ADCC).
Human wild type CD16 has a relatively
low affinity for IgG1 antibodies.
However, a single nucleotide
polymorphism (SNP rs396991) in the
CD16a gene (F to V at position 158;
referred to hereafter as HA–CD16)
results in substantially higher IgG1
affinity and superior NK mediated
ADCC.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive licenses, both
the one granted for the evaluation
period and if converted into a full
exclusive patent commercialization
license, will be royalty bearing. The
prospective exclusive license may be
granted unless within fifteen (15) days
from the date of this published notice,
the National Heart, Lung, and Blood
Institute receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this notice will be presumed
to contain business confidential
information and any release of
information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
VerDate Sep<11>2014
17:16 Aug 12, 2020
Jkt 250001
Dated August 5, 2020.
Michael Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2020–17703 Filed 8–12–20; 8:45 am]
National Institute of Nursing Research;
Notice of Meeting
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; PAR19–202: High
Impact, Interdisciplinary Science in NIDDK
Research Areas (RC2 Clinical Trial
Optional)—Hematological Diseases.
Date: September 28, 2020.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy Blvd.,
Bethesda, MD 20892 (Video Meeting).
Contact Person: Najma S. Begum, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7349, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8894,
begumn@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council for Nursing Research.
The meeting will be open to the
public as indicated below.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Nursing Research.
Date: September 15, 2020.
Open: 11:30 a.m. to 1:30 p.m.
Agenda: Discussion of Program Policies
and Issues.
Place: https://videocast.nih.gov/
watch=38169, Bethesda, MD 20892 (Virtual
Meeting).
Closed: 2:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Nursing
Research, National Institutes of Health, 6701
Democracy Boulevard, One Democracy Plaza,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Kay Wanke, Acting
Executive Secretary, National Institute of
Nursing Research, National Institutes of
Health, 6701 Democracy Boulevard, One
Democracy Plaza, Bethesda, MD 20817, (301)
402–0036, kay.wanke@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: www.nih.gov/
ninr/a_advisory.html, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.361, Nursing Research,
National Institutes of Health, HHS)
Dated: August 7, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: August 10, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–17677 Filed 8–12–20; 8:45 am]
[FR Doc. 2020–17743 Filed 8–12–20; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
PO 00000
Frm 00030
Fmt 4703
Sfmt 9990
E:\FR\FM\13AUN1.SGM
13AUN1
]]>Agencies
[Federal Register Volume 85, Number 157 (Thursday, August 13, 2020)]
[Notices]
[Page 49388]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-17677]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; PAR19-202: High Impact,
Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical
Trial Optional)--Hematological Diseases.
Date: September 28, 2020.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Blvd., Bethesda, MD 20892 (Video Meeting).
Contact Person: Najma S. Begum, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 7349, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-8894, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: August 7, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-17677 Filed 8-12-20; 8:45 am]
BILLING CODE 4140-01-P
